PGC1A is also negatively regulated by TRPV4, while TRPV4 antagonists reduce high‐fat diet‐induced obesity, insulin resistance, diabetic nephropathy, retinopathy, and neuropathy. This evidence concerns the gene PPARGC1A and diabetic kidney disease.